Want to see JBS full AI Analyst Report?
Top Page
JBS
(NYSE:JBS)
Select Model
Select Model
Rating:58Neutral
Price Target:
$14.00
▲(14.01% Upside)
Action:Reiterated
Date:08/19/26
Overall score reflects moderate fundamentals: earnings and cash flow have improved, but the sharp TTM revenue drop, margin compression, and leverage risk constrain financial strength. Technicals are mildly supportive and the high dividend yield helps valuation, while the latest call and proposed PPC consolidation are constructive but still tempered by higher interest costs, leverage above target, and ongoing segment pressures.
Positive Factors
Global diversification and value-added protein platform
JBS combines geographic reach, multiple animal-protein categories and branded or prepared foods. This diversification can reduce dependence on one market or commodity and supports more resilient customer coverage over time.
Negative Factors
Elevated leverage and rising interest burden
Leverage above target limits financial flexibility in a cyclical, commodity-exposed business. Higher interest expense can absorb cash that might otherwise support investment, deleveraging or shareholder distributions.
Read all positive and negative factors
Positive Factors
Negative Factors
Global diversification and value-added protein platform
JBS combines geographic reach, multiple animal-protein categories and branded or prepared foods. This diversification can reduce dependence on one market or commodity and supports more resilient customer coverage over time.
Read all positive factors
JBS (JBS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.80B
Dividend Yield7.24%
Average Volume (3M)5.51M
Price to Earnings (P/E)18.9
Beta (1Y)0.02
Revenue Growth334.15%
EPS Growth-18.31%
CountryUS
Employees283,000
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)3.75
Shares Outstanding776,086,900
10 Day Avg. Volume3,380,042
30 Day Avg. Volume5,506,259
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.76
Price to Sales (P/S)0.18
P/FCF Ratio20.44
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.10Price Target Upside47.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.01
Revenue Forecast (FY)$92.67B
JBS Business Overview & Revenue Model
Company Description
JBS S.A. (JBS) is a global food company primarily engaged in animal protein processing and branded food production. Through a portfolio of subsidiaries and brands, the company operates across beef, poultry, and pork processing, as well as value-ad...
How the Company Makes Money
JBS makes money by processing livestock into meat and prepared-food products and selling them through a mix of commodity and branded channels. Its core revenue model is volume-driven: it purchases cattle, chickens, and hogs (and related raw materi...
JBS Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Neutral
The call conveyed a mixed but resilient picture: several meaningful operational and strategic positives (record revenue, positive adjusted EBITDA, restored free cash flow, a major JV to accelerate Asia expansion, improved pork margins and progress in U.S. beef operations) were offset by material financial headwinds (a GAAP net loss driven by nonrecurring charges, a YoY EBITDA decline, higher financial expenses and interest costs, elevated capex, and leverage slightly above target). Management emphasized execution, cash generation and disciplined capital allocation while outlining pathways (Mexican border reopening, operational initiatives, JV funding) to improve performance.Positive Updates
Record Quarterly Revenue
Net sales reached a record $24.0 billion in Q2 2026, reflecting strong top-line performance across the global platform.
Negative Updates
Reported Net Loss and EPS Impacted by Nonrecurring Items
The quarter reported a net loss of $102 million and a negative EPS of $0.10. Excluding nonrecurring items management reported adjusted net income of $218 million and adjusted EPS of $0.20, highlighting material one-off impacts to GAAP results.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Quarterly Revenue
Net sales reached a record $24.0 billion in Q2 2026, reflecting strong top-line performance across the global platform.
Read all positive updates
Company Guidance
Management’s guidance emphasized cash generation and balance‑sheet repair with a 2026 cash‑flow breakeven EBITDA target of $5.1 billion, capital expenditures of $2.0 billion (down $400 million vs. initial estimates, including ~$159 million expansion CapEx in Q2), working capital expected at negative $350 million in 2026 (a $500 million improvement YoY), and $100 million of legal settlements already realized; other 2026 assumptions include biological assets of $850 million (flat vs. 2025), interest expense of ~$1.3 billion (up $150 million vs. prior plan), leasing expense of $500 million, and an effective tax rate of ~25%. Management also highlighted stronger liquidity (RCF increased from $3.5 billion to $4.2 billion and total cash + RCF ≈ $7.7 billion), an average debt term of 15.3 years at a 5.7% cost, no significant near‑term maturities, 35% of gross debt beyond 2050, and a Q2 free cash flow improvement to +$130 million (vs. -$55 million a year earlier) while net leverage finished Q2 at 3.1x (target 2–3x) with most free cash flow expected in H2.JBS Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
38
Negative
Cash Flow
57
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 382.19B | 471.14B | 416.95B | 363.82B | 383.97B | 362.50B |
| Gross Profit | 45.31B | 60.33B | 62.77B | 39.65B | 61.04B | 68.49B |
| EBITDA | 26.96B | 36.21B | 35.39B | 14.72B | 35.98B | 42.98B |
| Net Income | 6.41B | 11.10B | 9.62B | -1.06B | 15.85B | 21.24B |
Balance Sheet | ||||||
| Total Assets | 45.84B | 248.34B | 1.56T | 1.01T | 208.11B | 207.25B |
| Cash, Cash Equivalents and Short-Term Investments | 3.47B | 25.98B | 214.97B | 108.74B | 13.18B | 23.24B |
| Total Debt | 24.44B | 125.71B | 834.39B | 542.27B | 104.41B | 103.61B |
| Total Liabilities | 36.78B | 195.97B | 1.25T | 782.17B | 158.30B | 159.45B |
| Stockholders Equity | 8.22B | 47.87B | 276.92B | 213.08B | 46.34B | 44.12B |
Cash Flow | ||||||
| Free Cash Flow | 3.14B | 4.13B | 15.47B | 4.01B | 2.11B | 11.86B |
| Operating Cash Flow | 16.47B | 15.49B | 23.56B | 11.50B | 13.33B | 21.48B |
| Investing Cash Flow | -13.81B | -12.56B | -7.73B | -7.02B | -13.12B | -18.86B |
| Financing Cash Flow | 2.58B | -9.97B | -7.30B | 5.01B | -8.76B | -844.50M |
JBS Technical Analysis
Positive
12.28
Price Trends
12.76
Positive
13.59
Positive
13.74
Positive
Market Momentum
0.25
Positive
58.65
Neutral
63.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JBS, the sentiment is Positive. The current price of 12.28 is below the 20-day moving average (MA) of 13.70, below the 50-day MA of 12.76, and below the 200-day MA of 13.74, indicating a bullish trend. The MACD of 0.25 indicates Positive momentum. The RSI at 58.65 is Neutral, neither overbought nor oversold. The STOCH value of 63.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JBS.
JBS Risk Analysis
JBS disclosed 49 risk factors in its most recent earnings report. JBS reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
JBS Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $30.33B | -8.94 | -8.44% | 6.23% | -1.62% | 36.06% | |
68 Neutral | $7.68B | 14.02 | 14.85% | ― | 1.42% | -55.97% | |
67 Neutral | $13.29B | -95.63 | -2.44% | 3.72% | 3.72% | 88.76% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
58 Neutral | $14.80B | 18.93 | 17.67% | 8.14% | 334.15% | -18.31% | |
57 Neutral | $13.14B | 28.11 | 5.86% | 4.61% | 2.47% | -37.67% |
* Consumer Defensive Sector Average
JBS
JBS
13.88
-0.61
-4.20%
HRL
Hormel Foods
24.09
-3.34
-12.18%
SJM
JM Smucker
125.87
18.73
17.48%
PPC
Pilgrim's Pride
31.79
-13.27
-29.45%
KHC
Kraft Heinz
25.67
-0.28
-1.08%
JBS Corporate Events
Business Operations and StrategyM&A Transactions
JBS Moves to Fully Acquire Pilgrim’s Pride Shares
Positive
Aug 19, 2026
On August 18, 2026, JBS submitted a non-binding proposal to acquire all remaining Pilgrim’s Pride Corporation shares it does not already own via a stock-for-stock transaction offering 2.086 JBS Class A common shares for each PPC share. Based...
JBS Secures $2.5 Billion Indonesia Sovereign Fund Joint Venture to Expand Asia-Pacific Protein Business
Aug 7, 2026
On August 7, 2026, JBS N.V. announced that its subsidiary JBS USA Holding Lux S.à.r.l. has partnered with PT Danantara Investment Management, the investment arm of Indonesia’s sovereign wealth fund, to form a joint venture targeting pro...
JBS Expands Global Revolving Credit Capacity to US$4.2 Billion
Aug 5, 2026
On August 5, 2026, JBS N.V. and certain subsidiaries, including JBS S.A., executed a Sixth Amendment and Restatement Agreement to their Revolving Syndicated Facility, originally signed in November 2022. The amended agreement establishes a senior u...
JBS N.V. Details Governance Practices in Dual-Class Share Structure Filing
Jul 31, 2026
On July 31, 2026, JBS N.V. filed a Form 6-K with the U.S. Securities and Exchange Commission, disclosing its Brazilian Corporate Governance Report prepared in line with CVM Resolution 80/2022 and the Brazilian Corporate Governance Code for listed ...
JBS N.V. Files Form 6-K and Publishes New Investor Presentation
Jun 15, 2026
On June 15, 2026, JBS N.V. announced it had posted a new investor presentation in the “Presentations” section of its investor relations website. The materials will be used from June 15 onward in conferences and meetings with investors ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.